CRBP Corbus Pharmaceuticals Holdings Inc.

7.38
-0.35  -5%
Previous Close 7.73
Open 7.8
Price To Book 9.84
Market Cap 422412720
Shares 57,237,496
Volume 738,840
Short Ratio
Av. Daily Volume 811,499

SEC filingsSee all SEC filings

  1. 8-K - Current report 19503846
  2. CT ORDER - Confidential treatment order 181217541
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181168228
  4. 8-K - Current report 181168175
  5. SC 13G - Statement of acquisition of beneficial ownership by individuals 181143291

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b data due 2020.
Anabasum (Resunab)
Cystic Fibrosis
Phase 2 trial initiation announced December 22, 2017.
Anabasum (Resunab)
Systemic lupus erythematosus (SLE)
Phase 3 trial initiation announced December 17, 2018.
Lenabasum (resunab) - DETERMINE
Dermatomyositis
Phase 3 data due 2020.
Resunab
Systemic Sclerosis

Latest News

  1. Top Marijuana Stocks on the NASDAQ
  2. Implied Volatility Surging for Corbus Pharmaceuticals (CRBP) Stock Options
  3. Corbus Pharmaceuticals Announces Strategic Collaboration with Kaken Pharmaceutical Co., Ltd. to Develop and Commercialize Lenabasum in Japan for Systemic Sclerosis and Dermatomyositis
  4. Factors of Influence in 2019, Key Indicators and Opportunity within Halozyme Therapeutics, Capricor Therapeutics, Appian, Yext, Agile Therapeutics, and Corbus Pharmaceuticals — New Research Emphasizes Economic Growth
  5. Corbus Pharmaceuticals Announces Issuance of Composition of Matter Patent Related to Lenabasum
  6. Some of December's Most Interesting Stocks
  7. Vertex (VRTX) Gets Positive CHMP Opinion for Orkambi in Kids
  8. Edited Transcript of CRBP earnings conference call or presentation 8-Nov-18 1:30pm GMT
  9. Curaleaf Opens Medical Marijuana Dispensary in Tallahassee
  10. What to Expect from Cannabis Player Curaleaf’s Q3 Earnings
  11. Corbus Pharmaceuticals Holdings’ Performance in 2018
  12. Analyzing 22nd Century Group’s Year-to-Date Performance
  13. A Closer Look at Insys Therapeutics’ Performance Year-to-Date
  14. How Marijuana-Focused Biotech Companies Have Performed in 2018
  15. Corbus Pharmaceuticals (CRBP) Reports Q3 Loss, Misses Revenue Estimates
  16. Corbus Pharmaceuticals: 3Q Earnings Snapshot
  17. How Much Of Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) Do Insiders Own?
  18. Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in November

SEC Filings

  1. 8-K - Current report 19503846
  2. CT ORDER - Confidential treatment order 181217541
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181168228
  4. 8-K - Current report 181168175
  5. SC 13G - Statement of acquisition of beneficial ownership by individuals 181143291
  6. 8-K - Current report 181078722
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 181000008
  8. 8-K - Current report 18999996
  9. 8-K - Current report 18967822
  10. 8-K - Current report 18895969